Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody-chemo combo targets tough childhood cancer

NCT ID NCT07549321

First seen Apr 29, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps shrink or eliminate high-risk neuroblastoma in children and teens aged 1.5 to 18 years. Neuroblastoma is a rare but aggressive solid tumor that often spreads before diagnosis. The trial will enroll 144 participants across multiple countries to measure how many achieve a complete or partial response, and to monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Children's Hospital Colorado Anschutz Medical

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.